Search

Displaying results 2701 - 2710 of 4301 in total
  1. Drug

    Tegaserod

    go.drugbank.com/drugs/DB01079
    ApprovedWithdrawn

    [L5918,F4229] Zelnorm (tegaserod) by Sloan Pharma subsequently gained re-approval in April of 2019.[L5918] Nevertheless, tegaserod remains un-approved in certain regions.

  2. Drug

    VE303

    go.drugbank.com/drugs/DB17794
    Investigational

    VE303 is under clinical development by Vedanta Biosciences.

  3. Drug

    Medical Cannabis

    go.drugbank.com/drugs/DB14009
    Investigational

    Reliably studying the effects of Cannabis is complicated by the large variety of available strains and by the numerous other compounds that Cannabis contains such as terpenes, flavonoids, phenols, amino … While cannabis in its natural plant form is currently used "off-label" for the management of many medical conditions, THC is currently commercially available in synthetic form as [DB00486], as purified

  4. Drug

    Porphobilinogen

    go.drugbank.com/drugs/DB02272
    Experimental

    It is generated by the enzyme ALA dehydratase, and converted into hydroxymethyl bilane by the enzyme porphobilinogen deaminase.

  5. Drug

    Hyperforin

    go.drugbank.com/drugs/DB01892
    InvestigationalNutraceutical

    Hyperforin is a phytochemical generated by the plants of the Hypericum family.

  6. Drug

    Nalbuphine

    go.drugbank.com/drugs/DB00844
    ApprovedInvestigational

    A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the Un...

  7. Drug

    Insulin glulisine

    go.drugbank.com/drugs/DB01309
    Approved

    This recombinant hormone differs from native human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine at position B29 is replaced by glutamic acid. … Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.

  8. Drug

    PBI-1402

    go.drugbank.com/drugs/DB05480
    Experimental

    PBI-1402 appears to work on the PMN pathway, but its specific binding properties are not known. PBI-1402 has a dual therapeutic action; as a chemoprotectant and hematopoietic progenitor stimulator.

  9. Drug

    Bisegliptin

    go.drugbank.com/drugs/DB06127
    Investigational

    It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion

  10. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.